Skip to main content
Erschienen in: Endocrine 2/2016

30.10.2015 | Original Article

Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study

verfasst von: Yoshitaka Hashimoto, Muhei Tanaka, Hiroshi Okada, Kazuteru Mistuhashi, Toshihiro Kimura, Noriyuki Kitagawa, Takuya Fukuda, Saori Majima, Yukiko Fukuda, Yoshimitsu Tanaka, Shunji Yamada, Takafumi Senmaru, Masahide Hamaguchi, Mai Asano, Masahiro Yamazaki, Yohei Oda, Goji Hasegawa, Naoto Nakamura, Michiaki Fukui

Erschienen in: Endocrine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Taking metformin with a meal has been shown to decrease bioavailability of metformin. We hypothesized that taking metformin 30 min before a meal improves glucose metabolism. As an animal model, 18 Zucker-rats were divided into three groups as follows: no medication (Control), metformin (600 mg/kg) with meal (Met), and metformin 10 min before meal (pre-Met). In addition, five diabetic patients were recruited and randomized to take metformin (1000 mg) either 30 min before a meal (pre-Met protocol) or with a meal (Met protocol). In the animal model, the peak glucose level of pre-Met (7.8 ± 1.5 mmol/L) was lower than that of Control (12.6 ± 2.5 mmol/L, P = 0.010) or Met (14.1 ± 2.9 mmol/L, P = 0.020). Although there was no statistical difference among the three groups, total GLP-1 level at t = 0 min of pre-Met (7.4 ± 2.7 pmol/L) tended to be higher than that of Control (3.7 ± 2.0 pmol/L, P = 0.030) or Met (3.9 ± 1.2 pmol/L, P = 0.020). In diabetic patients, the peak glucose level of pre-Met protocol (7.0 ± 0.4 mmol/L) was lower than that of Met protocol (8.5 ± 0.9 mmol/L, P = 0.021). Total GLP-1 level at t = 30 min of pre-Met protocol (11.0 ± 6.1 pmol/L) was higher than that of Met protocol (6.7 ± 3.9 pmol/L, P = 0.033). Taking metformin 30 min before a meal ameliorated postprandial hyperglycemia. This promises to be a novel approach for postprandial hyperglycemia.
Literatur
1.
Zurück zum Zitat M.A. Espeland, H.A. Glick, A. Bertoni, F.L. Brancati, G.A. Bray, J.M. Clark, J.M. Curtis, C. Egan, M. Evans, J.P. Foreyt, S. Ghazarian, E.W. Gregg, H.P. Hazuda, J.O. Hill, D. Hire, E.S. Horton, V.S. Hubbard, J.M. Jakicic, R.W. Jeffery, K.C. Johnson, S.E. Kahn, T. Killean, A.E. Kitabchi, W.C. Knowler, A. Kriska, C.E. Lewis, M. Miller, M.G. Montez, A. Murillo, D.M. Nathan, E. Nyenwe, J. Patricio, A.L. Peters, X. Pi-Sunyer, H. Pownall, J.B. Redmon, J. Rushing, D.H. Ryan, M. Safford, A.G. Tsai, T.A. Wadden, R.R. Wing, S.Z. Yanovski, P. Zhang, Look AHEAD Research Group, Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes. Diabetes Care 37, 2548–2556 (2014)CrossRefPubMedPubMedCentral M.A. Espeland, H.A. Glick, A. Bertoni, F.L. Brancati, G.A. Bray, J.M. Clark, J.M. Curtis, C. Egan, M. Evans, J.P. Foreyt, S. Ghazarian, E.W. Gregg, H.P. Hazuda, J.O. Hill, D. Hire, E.S. Horton, V.S. Hubbard, J.M. Jakicic, R.W. Jeffery, K.C. Johnson, S.E. Kahn, T. Killean, A.E. Kitabchi, W.C. Knowler, A. Kriska, C.E. Lewis, M. Miller, M.G. Montez, A. Murillo, D.M. Nathan, E. Nyenwe, J. Patricio, A.L. Peters, X. Pi-Sunyer, H. Pownall, J.B. Redmon, J. Rushing, D.H. Ryan, M. Safford, A.G. Tsai, T.A. Wadden, R.R. Wing, S.Z. Yanovski, P. Zhang, Look AHEAD Research Group, Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: the action for health in diabetes. Diabetes Care 37, 2548–2556 (2014)CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, A. Sekikawa, Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22, 920–924 (1999)CrossRefPubMed M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, A. Sekikawa, Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22, 920–924 (1999)CrossRefPubMed
3.
Zurück zum Zitat T. Nakagami, Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47, 385–394 (2004)CrossRefPubMed T. Nakagami, Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47, 385–394 (2004)CrossRefPubMed
4.
Zurück zum Zitat F. Fehse, M. Trautmann, J.J. Holst, A.E. Halseth, N. Nanayakkara, L.L. Nielsen, M.S. Fineman, D.D. Kim, M.A. Nauck, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 90, 5991–5997 (2005)CrossRefPubMed F. Fehse, M. Trautmann, J.J. Holst, A.E. Halseth, N. Nanayakkara, L.L. Nielsen, M.S. Fineman, D.D. Kim, M.A. Nauck, Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 90, 5991–5997 (2005)CrossRefPubMed
5.
Zurück zum Zitat B. Balas, M.R. Baig, C. Watson, B.E. Dunning, M. Ligueros-Saylan, Y. Wang, Y.L. He, C. Darland, J.J. Holst, C.F. Deacon, K. Cusi, A. Mari, J.E. Foley, R.A. DeFronzo, The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 92, 1249–1255 (2007)CrossRefPubMed B. Balas, M.R. Baig, C. Watson, B.E. Dunning, M. Ligueros-Saylan, Y. Wang, Y.L. He, C. Darland, J.J. Holst, C.F. Deacon, K. Cusi, A. Mari, J.E. Foley, R.A. DeFronzo, The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 92, 1249–1255 (2007)CrossRefPubMed
6.
Zurück zum Zitat D. Kirpichnikov, S.I. McFarlane, J.R. Sowers, Metformin: an update. Ann. Intern. Med. 137, 25–33 (2002)CrossRefPubMed D. Kirpichnikov, S.I. McFarlane, J.R. Sowers, Metformin: an update. Ann. Intern. Med. 137, 25–33 (2002)CrossRefPubMed
7.
Zurück zum Zitat S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58, 429–442 (2015)CrossRefPubMed S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58, 429–442 (2015)CrossRefPubMed
8.
Zurück zum Zitat E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, E. Pierazzuoli, S. Ciani, G. Messeri, C.M. Rotella, Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24, 489–494 (2001)CrossRefPubMed E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, E. Pierazzuoli, S. Ciani, G. Messeri, C.M. Rotella, Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24, 489–494 (2001)CrossRefPubMed
9.
Zurück zum Zitat B.D. Green, N. Irwin, N.A. Duffy, V.A. Gault, F.P. O’harte, P.R. Flatt, Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur. J. Pharmacol. 547, 192–199 (2006)CrossRefPubMed B.D. Green, N. Irwin, N.A. Duffy, V.A. Gault, F.P. O’harte, P.R. Flatt, Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur. J. Pharmacol. 547, 192–199 (2006)CrossRefPubMed
10.
Zurück zum Zitat N.C. Sambol, L.G. Brookes, J. Chiang, A.M. Goodman, E.T. Lin, C.Y. Liu, L.Z. Benet, Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br. J. Clin. Pharmacol. 42, 510–512 (1996)CrossRefPubMed N.C. Sambol, L.G. Brookes, J. Chiang, A.M. Goodman, E.T. Lin, C.Y. Liu, L.Z. Benet, Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br. J. Clin. Pharmacol. 42, 510–512 (1996)CrossRefPubMed
11.
Zurück zum Zitat Y. Urita, K. Hike, N. Torii, Y. Kikuchi, M. Sasajima, K. Miki, Efficacy of lactulose plus 13C-acetate breath test in the diagnosis of gastrointestinal motility disorders. J. Gastroenterol. 37, 442–448 (2002)CrossRefPubMed Y. Urita, K. Hike, N. Torii, Y. Kikuchi, M. Sasajima, K. Miki, Efficacy of lactulose plus 13C-acetate breath test in the diagnosis of gastrointestinal motility disorders. J. Gastroenterol. 37, 442–448 (2002)CrossRefPubMed
12.
Zurück zum Zitat C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, A. Hincelin-Méry, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes. Metab. 15, 642–649 (2013)CrossRefPubMedPubMedCentral C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, A. Hincelin-Méry, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes. Metab. 15, 642–649 (2013)CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat J. Gagnon, E. Sheppard, Y. Anini, Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes. Metab. 15, 276–279 (2013)CrossRefPubMed J. Gagnon, E. Sheppard, Y. Anini, Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes. Metab. 15, 276–279 (2013)CrossRefPubMed
14.
Zurück zum Zitat Y. Masuda, T. Tanaka, N. Inomata, N. Ohnuma, S. Tanaka, Z. Itoh, H. Hosoda, M. Kojima, K. Kangawa, Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276, 905–908 (2000)CrossRefPubMed Y. Masuda, T. Tanaka, N. Inomata, N. Ohnuma, S. Tanaka, Z. Itoh, H. Hosoda, M. Kojima, K. Kangawa, Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276, 905–908 (2000)CrossRefPubMed
15.
Zurück zum Zitat J.J. Meier, G. Kemmeries, J.J. Holst, M.A. Nauck, Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54, 2212–2218 (2005)CrossRefPubMed J.J. Meier, G. Kemmeries, J.J. Holst, M.A. Nauck, Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54, 2212–2218 (2005)CrossRefPubMed
16.
Zurück zum Zitat A.J. Lee, Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 16, 327–351 (1996)PubMed A.J. Lee, Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 16, 327–351 (1996)PubMed
17.
Zurück zum Zitat J. Borovicka, C. Kreiss, K. Asal, B. Remy, C. Mettraux, A. Wells, N.W. Read, J.B. Jansen, M. D’Amato, A.B. Delaloye, M. Fried, W. Schwizer, Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am. J. Physiol. 271, G448–G453 (1996)PubMed J. Borovicka, C. Kreiss, K. Asal, B. Remy, C. Mettraux, A. Wells, N.W. Read, J.B. Jansen, M. D’Amato, A.B. Delaloye, M. Fried, W. Schwizer, Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am. J. Physiol. 271, G448–G453 (1996)PubMed
18.
Zurück zum Zitat F.H. Weber Jr, R.D. Richards, R.W. McCallum, Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am. J. Gastroenterol. 88, 485–490 (1993)PubMed F.H. Weber Jr, R.D. Richards, R.W. McCallum, Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am. J. Gastroenterol. 88, 485–490 (1993)PubMed
19.
Zurück zum Zitat J.M. Trujillo, W. Nuffer, GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy 34, 1174–1186 (2014)CrossRefPubMed J.M. Trujillo, W. Nuffer, GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy 34, 1174–1186 (2014)CrossRefPubMed
20.
Zurück zum Zitat N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine 47, 21–28 (2014)CrossRefPubMed N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine 47, 21–28 (2014)CrossRefPubMed
Metadaten
Titel
Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study
verfasst von
Yoshitaka Hashimoto
Muhei Tanaka
Hiroshi Okada
Kazuteru Mistuhashi
Toshihiro Kimura
Noriyuki Kitagawa
Takuya Fukuda
Saori Majima
Yukiko Fukuda
Yoshimitsu Tanaka
Shunji Yamada
Takafumi Senmaru
Masahide Hamaguchi
Mai Asano
Masahiro Yamazaki
Yohei Oda
Goji Hasegawa
Naoto Nakamura
Michiaki Fukui
Publikationsdatum
30.10.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0786-4

Weitere Artikel der Ausgabe 2/2016

Endocrine 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.